Pasithea Therapeutics Corp. — Director's Dealing 2024

Mar 2, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2024-03-01

Reporting Person: Dumesnil Simon (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-03-01	Stock Option (right to buy)	$8.34	A	7500	Acquired	2034-02-28	Common Stock (7500)	Direct

Footnotes

F1: The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date.